A case report of concurrent embryonal rhabdomyosarcoma and diffuse large B-cell lymphoma in an adult without identifiable cancer predisposition

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Rhabdomyosarcoma, the most common soft tissue sarcoma of childhood. makes up less than 1% of solid malignancies in adults with around 400 new cases each year in the United States. They have not previously been rep...

Full description

Saved in:
Bibliographic Details
Published in:Biomarker research 2017-02, Vol.5 (1), p.7, Article 7
Main Authors: Mathias, M D, Ortiz, M V, Magnan, H, Ambati, S R, Slotkin, E K, Chou, A J, Walsh, M F, Offit, K, Moskowitz, C, Kentsis, A, Wexler, L H
Format: Article
Language:English
Subjects:
Age
Cancer therapies
Care and treatment
Case Report
Case studies
Chemotherapy
Consent
Diagnosis
Family medical history
Genes
Lymphatic system
Lymphoma
Lymphomas
Morphology
Mutation
Pathology
Patients
Pneumonia
Prostate cancer
Rhabdomyosarcoma
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Rhabdomyosarcoma, the most common soft tissue sarcoma of childhood. makes up less than 1% of solid malignancies in adults with around 400 new cases each year in the United States. They have not previously been reported concurrently. A 37 year old woman presented with painful enlarging leg mass. Biopsy of the mass was consistent with embryonal rhabdomyosarcoma. Staging imaging revealed a PET avid anterior mediastinal lymph node. Excisional biopsy of this mass was consistent with diffuse large B-cell lymphoma. Hybridization capture-based next-generation DNA sequencing did not reveal shared somatic tumor mutations. Germline analysis did not show identifiable aberrations of or other heritable cancer susceptibility genes. She was treated with a personalized chemotherapy regimen combining features of R-CHOP and Children's Oncology Group ARST 0331. This case illustrates a unique clinical entity successfully treated with a personalized chemotherapeutic regimen.
ISSN:2050-7771
2050-7771
DOI:10.1186/s40364-017-0086-7